Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas

Neoplasma

Volumn 50, Issue 1, 2003, Pages 22-25

  Tothova E ^a   Kafkova A ^a   Guman, T ^a   Stecova N ^a   Fricova M ^a  

^a FACULTY HOSPITAL   (Slovakia)

Author keywords

Autologous transplantation; High dose chemotherapy; In vivo purging; Non Hodgkin's lymmphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE PHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0037269946     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. ADAM Z, MAYER J, VÁŠOVÁ I. Survey of experiences with highdose chemotherapy followed by autologous transplantation of hemopoietic cells in patients with follicular lymphomas and lymphoma of mantle cells (in Czech). Klin Onkol 1999; 12: 113-117.
2. DAVIS TA, GZILLO-LOPEZ AJ, WHITE CA. Rituximab anti CD20 monoclonal antibody therapy in non-Hodgkińs lymphoma. Safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
3. FLINN IW, BYRD J, HORRISON C, JAMISON J. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. J Clin Oncol 1998; 16: 3270-3278.
4. FRIEDBERG JW, FREDMAN AS. High dose therapy and stem cell transplantation in follicular lymphoma. Ann Haematol 1999; 78: 201-211.
5. GHIELMINI M. Prolonging remission with monoclonal antibody maintance therapy. Symposium Highlights ICML, Lugano 2002; 3-4.
6. GONZALES-BARCA E, FERNANDEZ A, DOMINO-CLAROS A, MARTIN-HENAO GA. Autologous stem cell transplantation (ASCT) with immunologic purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: Toxicity, follow up of minimal residual disease and survival. Bone Marrow Transplantation 2001; 26(10): 1051-1056.
7. GRATWOHL A. Number of patients transplanted in Europe in 1997. The EBMT Handbook Blood and Marrow Transplantation 2000; 22-23.
8. HAINSWORTH JD. Rituximab as first-line and maintance therapy for patients with indolent non-Hodgkin's lymphoma. Interim follow-up of a multicenter phase II trial 2002; 29: 25-29.
9. HESS GR. First-line treatment of indolent CD20 positive NHL with a combination of CHOP plus Rituximab followed by consolidation with high dose chemotherapy and PBSC transplantation. MabThera/Rituximab. Abstracts. ASH Annual Meeting, San Francisco, 2000; abst 1746.
10. HORNING SJ, NEGRIN RS, HOPPE RT, ROSENBERG SA. High-dose therapy and autologous bone marrow transplant in follicular lymphoma in first complete or partial remission. Blood 2001; 97: 404-409.
11. JOHNSON P. MabThera: Mechanism of action. Symposium Highlights ICML 2002; Lugano: 2.
12. McLAUGHUN P, GRILLO-LÓPEZ AJ, LINK BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
13. NAGLER A, SLAVIN S, VARDI G. PBSCT using a fludarabine based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplantation 2000; 25: 1021-1028.
14. 1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas (abstr). Proc Am Soc Clin Oncol 1998; 17: 3a.
15. SOUBEYRAN P, DEBLED M, TCHEN N, RICHAUD P. Follicular lymphomas - a review of treatment modalites. Crit Rev Oncol Hematol 2000; 35: 13-32.
16. TARELLA C. Negative immunomagnetic ex vivo purging combined with high dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long-term clinical and molecular remissions. Leukemia 1999; 13: 1456-1462.
17. ŠTECOVÁ N, TÓTUOVÁ E, ROSOCHA J. Relation between CFU GM and CD34+ doses and engraftment. Bone Marrow Transplantation 2002; 29: 198.
18. TÓTHOVÁ E, ŠTECOVÁ N, FRIČOVÁ M, KAFKOVÁ A. In vivo purging and autografting of CD 34+ cells in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation 2002; 29: 88.
19. VOSEJ M, LINK BK, CZUCZMAN M, GRILLO-LOPEZ A. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
20. VOSO MT, PANTEL G, WEISS M, SCHMIDT P, MARTIN S. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and Rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-735.
21. WITZING TE, WHITE CH, WISEMAN A. Phase I/II trial of IDECY2B8 radioimmunotherapy CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.